The Strategic Overview
For UK Pharmaceutical Procurement leaders, 2026 is the year of the “Margin Squeeze.” While raw material costs have stabilised, a new wave of “stealth taxes” and environmental mandates is threatening the bottom line. If your packaging strategy hasn’t been audited in the last six months, your 2026 budget may already be at risk.
- The Financial Impact: The £423/Tonne “Plastic Penalty”
The UK’s Extended Producer Responsibility (EPR) has fundamentally changed the “Should-Cost” model for secondary packaging.
- The Data: Base fees for plastic packaging are now estimated at £423 per tonne, compared to just £196 per tonne for paper and board.
- The Risk: Continuing to use plastic-heavy secondary packaging or non-recyclable coatings is effectively accepting a 115% premium on waste-management levies.
- The NHS “Right to Bid” (Evergreen Framework)
The NHS is no longer just a customer; it is a sustainability regulator. Under the NHS Net Zero Supplier Roadmap, suppliers must demonstrate carbon reduction to maintain their “Right to Bid.”
- The Deadline: By April 2027, all suppliers must report Global Scope 3 emissions.
- The Solution: Senior Managers are currently prioritising “Quick Wins”—such as moving to mono-material packaging—to boost their Evergreen Assessment scores before the next tender cycle.
- The “Mandatory Blister” Paradox
A common hurdle in Pharma is the regulatory necessity of plastic/foil blisters for drug stability. However, forward-thinking managers are finding savings in the “Layers of Protection”:
- Primary Packaging (The Blister): Exploring Mono-material Polypropylene (PP) to move the pack into “Recyclable” tax brackets.
- Secondary Packaging (The Box): Shifting from plastic-coated card to 100% uncoated fiber-based board to cut EPR fees by over 50%.
- Logistics: Using “Right-Sized” transit packaging to reduce total tonnage and transport emissions.
- The Windsor Framework & Northern Ireland
Post-Brexit compliance continues to add administrative weight. Ensuring your 2026 production runs meet the specific “UK Only” labelling requirements for Northern Ireland is essential to avoid supply chain bottlenecks and MHRA compliance audits.
Executive Action Plan for Q2:
- Perform a Material Audit: Identify every gram of plastic in your secondary packaging that can be switched to fiber.
- Review EPR Data: Ensure your reporting systems are accurate to prevent over-payment.
- Engage Supply Partners: Shift from “Transactional” buying to “Innovation” partnerships that focus on TCO (Total Cost of Ownership) rather than just unit price.
Is your 2026 packaging strategy resilient enough for these shifts?
At KERIMED PACKAGING SOLUTIONS, we help UK Pharma firms navigate EPR liabilities and NHS compliance through smarter material engineering.
[Contact Our Lead ravi@kerimed.co.uk]